Document Detail


Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.
MedLine Citation:
PMID:  20535013     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Venous thromboembolic disease, including deep vein thrombosis and pulmonary embolism, is a cause of significant mortality and morbidity. For several decades, anticoagulant options for the treatment and prevention of thrombosis have been limited mainly to agents such as unfractionated heparin and oral vitamin K antagonists, such as warfarin. Although these therapies have proven benefits, they also have important limitations that result in their underuse in routine clinical practice. A variety of novel anticoagulants with improved pharmacologic and clinical profiles are in development, offering benefits over traditional therapies. Specifically, progress has been made in the development of small molecule factor Xa inhibitors and thrombin inhibitors. With their potentially consistent and predictable clinical profile, oral formulation, and decreased need for coagulation monitoring, these new agents will likely increase the use and duration of anticoagulation treatment in thromboembolic disorders and reduce the burden associated with long-term management.
Authors:
Maryam Sattari; David T Lowenthal
Related Documents :
6492383 - Antithromboembolic treatment after cardiac valve replacement.
23291703 - Does electroconvulsive therapy cause epilepsy?
7890893 - Prevention of relapse in patients with chronic non-a, non-b/c hepatitis who respond to ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of therapeutics     Volume:  18     ISSN:  1536-3686     ISO Abbreviation:  Am J Ther     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-07-11     Completed Date:  2012-01-24     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  9441347     Medline TA:  Am J Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  332-8     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, University of Florida, College of Medicine, Gainesville, FL, USA. maryam.sattari@medicine.ufl.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Anticoagulants / therapeutic use*
Azetidines / therapeutic use
Benzimidazoles / therapeutic use*
Benzylamines / therapeutic use
Drug Approval
Humans
Morpholines / therapeutic use*
Pulmonary Embolism / drug therapy*
Pyrazoles / therapeutic use*
Pyridines / therapeutic use*
Pyridones / therapeutic use*
Thiophenes / therapeutic use*
United States
Venous Thrombosis / drug therapy*
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Azetidines; 0/Benzimidazoles; 0/Benzylamines; 0/Morpholines; 0/Pyrazoles; 0/Pyridines; 0/Pyridones; 0/Thiophenes; 0/rivaroxaban; 2E18WX195X/dabigatran etexilate; 3Z9Y7UWC1J/apixaban; 49HFB70472/ximelagatran

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Practitioners and nondrug treatment of hypertension, effects of participating in a survey.
Next Document:  Combination Therapy for Managing Difficult-to-Treat Patients With Stage 2 Hypertension: Focus on Val...